Shares of AstraZeneca plc (LON:AZN) have received an average rating of “Hold” from the thirty brokerages that are covering the firm, Market Beat reports. Four research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and fourteen have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is GBX 4,858.76 ($72.30).
In related news, insider Courtois,Jean-Philippe purchased 900 shares of AstraZeneca plc stock in a transaction on Tuesday, October 27th. The shares were purchased at an average price of GBX 4,423 ($65.82) per share, for a total transaction of £39,807 ($59,236.61).
Shares of AstraZeneca plc (LON:AZN) traded down 2.6102% on Monday, hitting GBX 4496.0000. The company had a trading volume of 1,051,870 shares. The firm has a 50-day moving average price of GBX 4,427.61 and a 200 day moving average price of GBX 4,259.49. AstraZeneca plc has a 12-month low of GBX 3,746.00 and a 12-month high of GBX 4,931.68. The company’s market capitalization is GBX 56.83 billion.
A number of research firms have weighed in on AZN. Kepler Capital Markets restated a “reduce” rating and issued a GBX 3,700 ($55.06) price target on shares of AstraZeneca plc in a research note on Monday, September 14th. Bryan Garnier & Cie restated a “buy” rating and issued a GBX 5,100 ($75.89) price target on shares of AstraZeneca plc in a research note on Friday, October 23rd. HSBC restated a “buy” rating and issued a GBX 4,910 ($73.07) price target on shares of AstraZeneca plc in a research note on Wednesday, December 23rd. Handelsbanken restated an “accumulate” rating and issued a GBX 4,959.33 ($73.80) price target on shares of AstraZeneca plc in a research note on Friday, December 4th. Finally, BNP Paribas restated an “outperform” rating and issued a GBX 5,500 ($81.85) price target on shares of AstraZeneca plc in a research note on Friday, September 11th.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company’s pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.